Matches in Wikidata for { <http://www.wikidata.org/entity/Q93218186> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q93218186 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q93218186 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93218186 description "scientific article published on 24 April 2020" @default.
- Q93218186 description "wetenschappelijk artikel" @default.
- Q93218186 description "наукова стаття, опублікована 24 квітня 2020" @default.
- Q93218186 name "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 name "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 type Item @default.
- Q93218186 label "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 label "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 prefLabel "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 prefLabel "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 P1433 Q93218186-329D7686-E12F-43E7-B726-EF2A0B31A03C @default.
- Q93218186 P1476 Q93218186-0A72196B-8397-49D2-9DEC-DA95E9462BEC @default.
- Q93218186 P2093 Q93218186-BBB0507F-7BC7-4E66-9D6F-262A80176514 @default.
- Q93218186 P2860 Q93218186-189D7EF6-52A0-45A0-BFE7-7ED0121BE91E @default.
- Q93218186 P2860 Q93218186-2D49915A-649A-4338-989B-2D3F7137D68C @default.
- Q93218186 P2860 Q93218186-907B7F9A-0673-4AB9-A92E-9F0A501112AE @default.
- Q93218186 P304 Q93218186-BD14B51F-DB54-4080-A2A2-22709F04F48D @default.
- Q93218186 P31 Q93218186-C6BE9228-0908-484A-96E4-991AD1C29EA9 @default.
- Q93218186 P356 Q93218186-06E94DD7-4DB0-45A4-91CE-3640BF6BA952 @default.
- Q93218186 P433 Q93218186-E3E3FFD1-BF48-4567-9F89-7AA159D3036D @default.
- Q93218186 P478 Q93218186-1340223F-FBBC-4D04-88FE-69643095D2F9 @default.
- Q93218186 P577 Q93218186-9B21EAF9-84C6-482C-B2CA-D19B938FCCF3 @default.
- Q93218186 P6179 Q93218186-41DDAC97-5FA6-400F-9767-AC6E137571CF @default.
- Q93218186 P698 Q93218186-7D8D97D7-2DD2-4F85-86A2-DC194972B156 @default.
- Q93218186 P921 Q93218186-0937CF21-0868-486A-8D05-688E3E4C97EA @default.
- Q93218186 P921 Q93218186-5766A66F-110D-4082-978C-6C8C7D7E1267 @default.
- Q93218186 P921 Q93218186-E6A6B3C1-7D48-46B5-BBEC-46DF3C225DB8 @default.
- Q93218186 P932 Q93218186-D263B7CB-CC5C-463A-80CF-3A571317D7D4 @default.
- Q93218186 P356 S12032-020-01376-8 @default.
- Q93218186 P698 32333196 @default.
- Q93218186 P1433 Q2152666 @default.
- Q93218186 P1476 "Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak" @default.
- Q93218186 P2093 "Ozgur Tanriverdi" @default.
- Q93218186 P2860 Q36665022 @default.
- Q93218186 P2860 Q89934806 @default.
- Q93218186 P2860 Q90365260 @default.
- Q93218186 P304 "51" @default.
- Q93218186 P31 Q13442814 @default.
- Q93218186 P356 "10.1007/S12032-020-01376-8" @default.
- Q93218186 P433 "6" @default.
- Q93218186 P478 "37" @default.
- Q93218186 P577 "2020-04-24T00:00:00Z" @default.
- Q93218186 P6179 "1126910640" @default.
- Q93218186 P698 "32333196" @default.
- Q93218186 P921 Q425088 @default.
- Q93218186 P921 Q485831 @default.
- Q93218186 P921 Q84263196 @default.
- Q93218186 P932 "7180657" @default.